Back to top
more

Biodesix (BDSX)

(Real Time Quote from BATS)

$1.62 USD

1.62
90,719

+0.03 (1.89%)

Updated Aug 8, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of 11.11% and 11.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Surpasses Q2 Earnings Estimates

Organon (OGN) delivered earnings and revenue surprises of 5.66% and 1.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Tops Q2 Earnings Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 9.13% and 0.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?

Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 16.84% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

Improving membership levels, strategic acquisitions, expanding government business, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.

Elevance Health (ELV) Enhances Whole Health With Paragon Buyout

Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Here's Why You Should Retain Teladoc (TDOC) Stock for Now

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

PacBio's (PACB) product development activities raise optimism about the stock.

Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.